subject: Stem Cell Therapy For Peripheral Arterial Disease-market Research Report [print this page] Stem cell therapy is relatively new and fast developing field. There is huge interest among general public, patients suffering from incurable and difficult to cure diseases, professionals, scientists and investors in this area of therapeutic medicine. Significant stem cell research has grown rapidly in the past few years, with series of important discoveries, such as induced pluripotent stem, or iPS, cells and engineered stem/progenitor cells. Today there are at least 17 R & D stem cell-based products for the treatment of peripheral arterial disease which are undergoing development by a number of companies worldwide with intention to be commercialized. In addition, a vast array of universities, institutions and government agencies are conducting their own research in this field.
Stem cell-based therapies for peripheral arterial disease are expected to fulfill two goals to be efficient: they have to provide better circulation through angiogenesis or neoangiogenesis, and to regenerate lost muscle and other tissues in the affected limb.
Stem Cell Therapy for Peripheral Arterial Disease report features 17 R & D product profiles, 21 company profiles and investors information. This report emphasizes advantages and disadvantages of particular cell therapies for peripheral arterial disease, characteristics and origin of used cells, mechanism of their action, types of delivery, efficacy and adverse effects, design of clinical trials and results of completed clinical studies and clinical trials.
Analysis reveals that high percentage (53%) of all stem cell-based R & D products for the treatment of peripheral arterial disease are in clinical stage of development. Adult stem cells and their progeny are dominant in this pipeline, with 94% of all products. Only one product is based on embryonic stem cells.
Expects that this pipeline, together with stem cell pipeline for the treatment of cardiac diseases, will produce one of the first approved stem cell-based therapeutic products. Also, in the future, stem cell-based products for the treatment of peripheral arterial disease will use more endothelial progenitor cells instead of undifferentiated mesenchymal and mesenchymal-like stem cells.
